Maravai LifeSciences Holdings, Inc. Class A Common Stock
MRVI
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Last trade$7.28
Day change-$0.125 (-1.69%)
Day range$7.17 – $7.53
Volume535,801
Market cap$1.10B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.1B
Price / earnings
—
Price / book
5.64×
Price / sales
5.19×
EV / sales
5.67×
EV / EBITDA
-176.88×
Profitability
Earnings per share
-$0.44
Return on assets
-10.94%
Return on equity
-33.52%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.9×
Current ratio
4.66×
Quick ratio
3.35×
Cash ratio
2.21×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MRVI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$45.85M
$51.44M
$65.84M
$49.87M
$41.63M
$47.4M
$46.85M
$56.56M
Cost of revenue
$29.66M
$30.79M
$32.14M
$37.02M
$35.98M
$39.63M
$39.13M
$37.17M
Gross profit
$16.19M
$20.65M
$33.7M
$12.84M
$5.66M
$7.77M
$7.73M
$19.39M
Selling, general and administrative
$30.5M
$32.07M
$29.09M
$31.58M
$35.46M
$38.72M
$39.56M
$41.24M
Research and development
$3.39M
$3.7M
$3.89M
$3.79M
$3.84M
$4.88M
$4.89M
$4.56M
Total operating expenses
$36.81M
$35.74M
$35.86M
$71.64M
$46.69M
$74.05M
$56.89M
$57.09M
Operating income
-$20.62M
-$15.09M
-$2.16M
-$58.8M
-$41.03M
-$66.28M
-$49.16M
-$37.7M
Interest expense
-$4.03M
-$4.81M
-$5.75M
-$6.56M
-$6.84M
-$6.82M
-$6.78M
-$11.26M
Income before taxes
-$24.08M
-$21.8M
-$6.53M
-$63.01M
-$45.15M
-$74.13M
-$52.69M
-$46.07M
Income taxes
-$75K
-$171K
-$151K
$6K
-$92K
-$4.29M
$162K
-$7K
Net income
-$24M
-$21.63M
-$6.38M
-$63.02M
-$45.06M
-$69.84M
-$52.85M
-$46.07M
Net income attributable to common shareholders
-$13.84M
-$12.42M
-$3.73M
-$35.68M
-$25.56M
-$39.59M
-$29.95M
-$25.91M
EBITDA
-$5.5M
-$3.34M
$12.09M
-$10.08M
-$20.46M
-$22.67M
-$24M
-$13.42M
Basic earnings per share
-$0.09
-$0.08
-$0.02
-$0.25
-$0.18
-$0.27
-$0.21
-$0.18
Diluted earnings per share
-$0.09
-$0.08
-$0.02
-$0.25
-$0.18
-$0.27
-$0.21
-$0.18
Recent news
Company coverage with links to the original publishers.
Maravai LifeSciences reported a Q3 loss of $0.03 per share, beating the consensus estimate of $0.05 loss, with a 40% earnings surprise. Revenue of $45.85 million exceeded estimates by 6.66%, up from $41.63 million year-over-year. The stock has gained 129.2% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Maravai LifeSciences is under investigation for potential financial reporting irregularities, including revenue recognition errors and potential goodwill impairment, which led to a significant stock price drop.
Maravai LifeSciences is under investigation for potential financial reporting irregularities, including revenue recognition errors and potential goodwill impairment, which led to a significant stock price drop.
Law firm investigating potential claims against Maravai LifeSciences for alleged financial reporting irregularities, including revenue recognition errors and potential goodwill impairment during fiscal 2024.
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (MRVI) for alleged violations of federal securities laws, including inaccurate revenue recognition and overstated goodwill.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.